Omeprazole vs Rabeprazole
## Overview
Rabeprazole has the most rapid onset of action among PPIs (activated faster in the parietal cell canaliculus) and the least dependence on CYP2C19 for its metabolism, resulting in less pharmacogenomic variability. It is useful in patients who are CYP2C19 ultra-rapid metabolizers.
## Mechanism of Action
Both irreversibly inhibit H+/K+-ATPase. Rabeprazole's thioether moiety activates more rapidly at physiological canalicular pH (~1) than other PPIs, potentially explaining faster onset of acid suppression.
## Pharmacokinetics
Rabeprazole: primarily non-enzymatic metabolism (hydrolysis) plus minor CYP2C19 and CYP3A4, half-life ~1–2 h. Omeprazole: primarily CYP2C19, more subject to pharmacogenomic variability.
## Clinical Considerations
CYP2C19 ultra-rapid metabolizers (common in East Asian and White populations) may have insufficient acid suppression with omeprazole, but rabeprazole maintains consistent efficacy across genotypes due to non-enzymatic elimination. Rabeprazole is also associated with less clopidogrel interaction than omeprazole.
## Key Takeaways
- Rabeprazole: fastest onset, least CYP2C19 dependence, consistent across CYP2C19 genotypes
- Omeprazole: more variable across CYP2C19 phenotypes
- Both equally effective for standard indications
結論
Rabeprazole is preferred in patients with CYP2C19 ultra-rapid metabolizer status or when consistent acid suppression regardless of pharmacogenomics is desired. For most patients, omeprazole and rabeprazole are clinically equivalent; cost typically favors generic omeprazole.